Evidence map›Paper›PMID 31347978›Full record

ArticleJournal of managed care & specialty pharmacy2019

Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned.

Anna Hung, Amy Lugo, C Daniel Mullins

Abstract read
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anna Hung1Duke Clinical Research Institute, Durham, North Carolina.
Amy Lugo2Defense Health Agency, San Antonio, Texas.
C Daniel Mullins3University of Maryland School of Pharmacy, Baltimore.

Funding

Budget Impact of Antidiabetic Formulary ChangesF32HS024857 · AHRQ · UNIVERSITY OF MARYLAND BALTIMORE · PI HUNG, ANNA · 2016 to 2017
$59k
AHRQ HHS F32 HS024857
6 · The paper itself

Abstract

Historically, budget impact models have been used to demonstrate how a new drug or technology entering the market could influence payer budgets, with the hope of influencing coverage of the drug or technology. This article proposes the adaptation of a budget impact model framework to answer the payer question "What is the budget impact of our approaches to managing the utilization of drugs and technologies?" Throughout this article, we also describe lessons learned while collaborating with a U.S. payer to evaluate the budgetary impact of specific antidiabetic drug utilization management approaches. DISCLOSURES: The study discussed in this commentary was supported by grant number F32HS024857 from the Agency for Healthcare Research and Quality (AHRQ). The content is solely the responsibility of the authors and does not necessarily represent the official views of AHRQ, which had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or design to submit the manuscript for publication. The findings discussed in this manuscript represent the views of the authors and do not necessarily reflect the views of the Department of Defense, the Defense Health Agency, nor the Departments of the Army, Navy, and Air Force. Hung reports personal fees from CVS Health and BlueCross BlueShield Association, outside the submitted work. Lugo has nothing to disclose. Mullins reports grants and other fees from AHRQ, during the conduct of the study; grants and personal fees from Bayer and Pfizer; and personal fees from Boehringer-Ingelheim, Janssen/J&J, Regeneron, and Sanofi, outside the submitted work. Parts of the study were presented as a poster presentation at the 2017 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 27-30, 2017; Denver, CO, and as poster and oral presentations at the 2017 AMCP Nexus Meeting; October 16-19, 2017; Dallas, TX. The study was also published as Hung's PhD dissertation.

Indexed as

BudgetsDrug CostsHumansHypoglycemic AgentsManaged Care ProgramsModels, EconomicUnited StatesHypoglycemic Agents

Identifiers

PMID31347978
PMCPMC7493826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.